The Core Difference Between DAC and No-DAC Variants
CJC-1295 No DAC is a synthetic peptide analog of human growth hormone-releasing hormone (GHRH), also categorized as modified GRF (1-29). Its key structural feature is the lack of the Drug Affinity Complex (DAC), a C-terminal molecular modification engineered to bind serum albumin and prolong circulatory retention. Analytical and regulatory research confirms that DAC and no-DAC variants are chemically distinct compounds, and pervasive naming inconsistency across published materials creates significant barriers to reliable data comparison and research reproducibility.
Signaling Along the GH/IGF-1 Axis
At the cellular level, CJC-1295 No DAC interacts with GHRH receptors located on anterior pituitary somatotroph cells. This binding initiates intracellular cyclic AMP-mediated signaling pathways, promoting the synthesis and pulsatile release of growth hormone (GH). Circulating GH subsequently stimulates hepatic production of insulin-like growth factor 1 (IGF-1), a key mediator of growth and metabolic signaling. This endogenous axis is tightly regulated by feedback loops involving somatostatin, ghrelin, and IGF-1 itself; pathway activation does not inherently equate to proven clinical benefits.
Current Evidence and Critical Gaps
The majority of published human data for CJC-1295 derives from small-scale studies of the DAC-containing formulation in healthy adult volunteers, which observed measurable increases in circulating GH and IGF-1 concentrations. There are no completed controlled clinical trials evaluating the no-DAC variant in patient cohorts with diagnosed health conditions. One registered study focused on HIV-associated visceral obesity was terminated prematurely without generating efficacy conclusions. Common claims related to body composition and metabolic effects remain unsubstantiated by targeted clinical research for this specific variant.
Regulatory and Safety Research Perspectives
No form of CJC-1295 No DAC holds FDA approval as a therapeutic agent, meaning there is no formally vetted safety or efficacy profile for clinical application. Regulatory assessments of compounded CJC-1295-related materials have flagged unresolved concerns around immunogenic potential, peptide-related impurities, and challenges in active ingredient characterization. Long-term safety data, disease-specific efficacy evaluations, and formal drug interaction studies for the no-DAC formulation remain largely unaddressed in peer-reviewed scientific literature.
Shaanxi Medibridge Biotech Co., Ltd. provides research peptides for laboratories, academic institutions, and biotechnology organizations worldwide. If you need a high‑purity peptide partner for enduring cooperation, email hi@medibridgeapi.com.
